The expression statuses of YB-1 and Ser-102-phosphorylated YB-1 have been described to be reversely correlated with clinical outcomes, such as in diffuse large B-cell lymphoma patients [6]. This evidence concerns the gene YBX1 and diffuse large B-cell lymphoma.